VRXA Short Volume
Veraxa Biotech Holding AG (VRXA) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $299.8M, listed on NASDAQ, employing roughly 8 people, carrying a beta of 0.25 to the broader market. Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company, formed via a merger with Voyager Acquisition Corp. Led by Christoph Antz, public since 2026-06-09.
Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.
- Latest Date
- 2026-07-16
- Short Volume
- 16.2K
- Total Volume
- 67.8K
- Short %
- 23.98%
- 30-Day Avg Short %
- 44.18%
Showing 24 days of FINRA short volume data for Veraxa Biotech Holding AG.
Learn how short volume is reported and how to read the data →
Frequently asked VRXA short volume questions
- What is the daily VRXA short volume?
- As of Jul 16, 2026, Veraxa Biotech Holding AG (VRXA) short volume is 16.2K shares against 67.8K total reported volume, or 23.98% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
- How is VRXA short volume reported?
- FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
- What does VRXA short volume tell options traders?
- Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.